161 related articles for article (PubMed ID: 26639833)
1. Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses.
Serrano-Rodríguez JM; Gómez-Díez M; Esgueva M; Castejón-Riber C; Mena-Bravo A; Priego-Capote F; Serrano Caballero JM; Muñoz A
Vet J; 2016 Feb; 208():38-43. PubMed ID: 26639833
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses.
Serrano-Rodríguez JM; Gómez-Díez M; Esgueva M; Castejón-Riber C; Mena-Bravo A; Priego-Capote F; Ayala N; Caballero JMS; Muñoz A
Res Vet Sci; 2017 Oct; 114():117-122. PubMed ID: 28371693
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat in healthy cats.
Desmoulins PO; Burgaud S; Horspool LJ
J Vet Pharmacol Ther; 2008 Aug; 31(4):349-58. PubMed ID: 18638296
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate.
Lefebvre HP; Jeunesse E; Laroute V; Toutain PL
J Vet Intern Med; 2006; 20(3):499-507. PubMed ID: 16734081
[TBL] [Abstract][Full Text] [Related]
5. Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.
Levitt DG; Schoemaker RC
BMC Clin Pharmacol; 2006 Jan; 6():1. PubMed ID: 16398929
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril.
van Griensven JM; Schoemaker RC; Cohen AF; Luus HG; Seibert-Grafe M; Röthig HJ
Eur J Clin Pharmacol; 1995; 47(6):513-8. PubMed ID: 7768254
[TBL] [Abstract][Full Text] [Related]
7. Modulation of acute transient exercise-induced hypertension after oral administration of four angiotensin-converting enzyme inhibitors in normotensive horses.
Muñoz A; Esgueva M; Gómez-Díez M; Serrano-Caballero JM; Castejón-Riber C; Serrano-Rodríguez JM
Vet J; 2016 Feb; 208():33-7. PubMed ID: 26626097
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibition in cirrhotic patients--pharmacokinetics of ramipril.
Pidlich J; Cichini GM; Reinisch W; Peck-Radosavljevic M; Renner F
Acta Med Austriaca; 1997; 24(1):15-8. PubMed ID: 9150805
[TBL] [Abstract][Full Text] [Related]
9. Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog.
Nordström M; Abrahamsson T; Ervik M; Forshult E; Regårdh CG
J Pharmacol Exp Ther; 1993 Jul; 266(1):147-52. PubMed ID: 8331554
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses.
Gómez-Díez M; Muñoz A; Caballero JM; Riber C; Castejón F; Serrano-Rodríguez JM
Res Vet Sci; 2014 Aug; 97(1):105-10. PubMed ID: 24972864
[TBL] [Abstract][Full Text] [Related]
11. High-performance liquid chromatography-mass spectrometric analysis of ramipril and its active metabolite ramiprilat in human serum: application to a pharmacokinetic study in the Chinese volunteers.
Lu XY; Shen-Tu JZ; Liu J
J Pharm Biomed Anal; 2006 Feb; 40(2):478-83. PubMed ID: 16181761
[TBL] [Abstract][Full Text] [Related]
12. Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study.
Beermann B; Nyquist O; Höglund C; Jacobsson KA; Näslund U; Jensen-Urstad M
Eur J Clin Pharmacol; 1993; 45(3):241-6. PubMed ID: 8276048
[TBL] [Abstract][Full Text] [Related]
13. Effects of quinapril on angiotensin converting enzyme and plasma renin activity as well as pharmacokinetic parameters of quinapril and its active metabolite, quinaprilat, after intravenous and oral administration to mature horses.
Davis JL; Kruger K; LaFevers DH; Barlow BM; Schirmer JM; Breuhaus BA
Equine Vet J; 2014 Nov; 46(6):729-33. PubMed ID: 24175935
[TBL] [Abstract][Full Text] [Related]
14. Lack of interaction between ramipril and simvastatin.
Meyer BH; Scholtz HE; Müller FO; Luus HG; de la Rey N; Seibert-Grafe M; Eckert HG; Metzger H
Eur J Clin Pharmacol; 1994; 47(4):373-5. PubMed ID: 7875191
[TBL] [Abstract][Full Text] [Related]
15. Lack of male-female differences in disposition and esterase hydrolysis of ramipril to ramiprilat in healthy volunteers after a single oral dose.
Vree TB; Dammers E; Ulc I; Horkovics-Kovats S; Ryska M; Merkx ; Ijsbrand
ScientificWorldJournal; 2003 Dec; 3():1332-43. PubMed ID: 14755115
[TBL] [Abstract][Full Text] [Related]
16. Tight binding of ramiprilat to ACE: consequences for pharmacokinetic and pharmacodynamic measurements.
Brockmeier D
Int J Clin Pharmacol Ther; 1995 Dec; 33(12):631-8. PubMed ID: 8963479
[TBL] [Abstract][Full Text] [Related]
17. Kinetics, safety, and efficacy of ramipril after long-term administration in hemodialyzed patients.
Fillastre JP; Baguet JC; Dubois D; Vauquier J; Godin M; Legallicier B; Luus HG; de la Rey N; Carcone N; Genthon R
J Cardiovasc Pharmacol; 1996 Feb; 27(2):269-74. PubMed ID: 8720427
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV).
Gerckens U; Grube E; Mengden T; Sigel H; Wagner WL; Lahn T; Irmisch R; Metzger H
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S49-51. PubMed ID: 2474102
[TBL] [Abstract][Full Text] [Related]
19. Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure.
Heintz B; Verho M; Brockmeier D; Lückel G; Maigatter S; Sieberth HG; Rangoonwala B; Bender N
J Cardiovasc Pharmacol; 1993; 22 Suppl 9():S36-42. PubMed ID: 7514239
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man.
Verho M; Luck C; Stelter WJ; Rangoonwala B; Bender N
Curr Med Res Opin; 1995; 13(5):264-73. PubMed ID: 7555035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
